Article Dans Une Revue Multiple Sclerosis Journal Année : 2024

Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis

Elisabeth Maillart

Résumé

Recent studies in adults suggested that extended-interval dosing of rituximab/ocrelizumab (RTX/OCR) larger than 12 months was safe and could improve safety. This was an observational cohort study of very active pediatric-onset multiple sclerosis (PoMS) (median (range) age, 16 (12–17) years) treated with RTX/OCR with 6 month standard-interval dosing ( n = 9) or early extended-interval dosing ( n = 12, median (range) interval 18 months (12–25)). Within a median (range) follow-up of 31 (12–63) months after RTX/OCR onset, one patient (standard-interval) experienced relapse and no patient showed disability worsening or new T2-weighted lesions. This study suggests that the effectiveness of RTX/OCR is maintained with a median extended-interval dosing of 18 months in patients with very active PoMS.

Fichier non déposé

Dates et versions

hal-04946595 , version 1 (13-02-2025)

Identifiants

Citer

Melany Venet, Anne Lepine, Adil Maarouf, Damien Biotti, Clémence Boutiere, et al.. Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis. Multiple Sclerosis Journal, 2024, 30 (2), pp.261-265. ⟨10.1177/13524585231223069⟩. ⟨hal-04946595⟩
124 Consultations
0 Téléchargements

Altmetric

Partager

  • More